Novacyt S.A. (NCYT.L)
LSE · GBp · Healthcare · Medical Devices
£38.00 (-1.68%) as of
Key statistics
- Market cap
- 27.56M
- Forward P/E
- -5.46
- EPS (TTM)
- -0.31
- Dividend yield
- 0.00%
- 52-week range
- 26.60 – 86.00
- Beta
- 1.04
- Revenue (TTM)
- 21.79M
- Profit margin
- -102.49%
- Analyst target
- £66.00
- Volume
- 51.78k
About Novacyt S.A.
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Le Vésinet, France
- Employees
- 228
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.